The positive rate of CNN2 mRNA expression in lung cancer, HCC, gastric cancer, and nasopharyngeal cancer was 17.5% (7/40 cases), 50.0% (27/54 cases), 10.0% (4/40 cases), and 20.0% (8/40 cases), respectively (Figure 4A). This evidence concerns the gene CNN2 and hepatocellular carcinoma.